I'll be hosting a Twitter chat on Thursday afternoon--3:30 pm EST--with Dr. David Porter, one of the top investigators on the CAR-T team at the University of Pennsylvania. The use of this new technology to genetically engineer a T cell to track down and destroy cancer cells has been tapped as one of the top programs in the pipeline at Novartis ($NVS), which has bankrolled an ambitious effort to push through the clinic with a leading program.
With ASCO looming, Porter and I will be reviewing some of the highlights expected at the big cancer meeting, along with a discussion about how this program promises to be a game changer in cancer treatment.
This will be the first of three Twitter chats we're hosting on the FierceBiotech handle. Damian Garde will follow up with a Fierce conversation with ISI's Mark Schoenebaum on Sunday. And Eric Palmer will continue the discussion with Jonathan Gardner, the deputy news editor at EP Vantage, next week. You can follow all the action on your regular Twitter channel or by plugging into the hashtag #FierceASCO.
Check out the link for details. -- John Carroll, editor-in-chief (email | Twitter)